Armstrong Investigation (1905)

The Armstrong Investigation was a study commissioned by President Theodore Roosevelt in 1905 to investigate working conditions and safety concerns in the meatpacking industry. The investigation led to the passage of the Meat Inspection Act and the Pure Food and Drug Act, which were aimed at improving food safety and protecting consumers.

While the Armstrong Investigation did not directly impact employee benefits, it did set a precedent for government intervention in workplace safety and health, which has since been expanded to cover a wide range of employment-related issues. Today, employees are entitled to certain workplace protections, such as the right to a safe and healthy work environment, regardless of industry or occupation.

In terms of employee benefits, the Armstrong Investigation and subsequent legislation played a role in shaping the overall employment landscape and influencing the development of employee benefits programs. For example, many employee benefits, such as health insurance and retirement plans, are now governed by federal laws such as the Employee Retirement Income Security Act (ERISA) and the Affordable Care Act (ACA), which provide certain protections for employees and require employers to meet certain standards in terms of plan design and administration.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.